Review Article
Mesenchymal Stem Cell Transplantation for Liver Cell Failure: A New Direction and Option
Table 1
Demographic and clinical features at enrollment in clinical trials.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Data are expressed as mean ± standard deviation. NA: not available; ACLF: acute-on-chronic liver failure; UCMSC: umbilical cord-derived mesenchymal stem cell; BMSC: bone marrow-derived mesenchymal stromal cell; HSC: hematopoietic stem cell; ALB: albumin; ALT: alanine aminotransferase; AST: aspartate transaminase; TBIL: total bilirubin; DBIL: direct bilirubin; PT: prothrombin time; INR: international normalized ratio; Cr: creatinine; MELD: model for end-stage liver disease score; QoL: quality of life; CT: computed tomography scan: MRI: magnetic resonance imaging; US: ultrasonography. |